Stories
Slash Boxes
Comments

SoylentNews is people

posted by janrinok on Sunday April 15 2018, @06:48AM   Printer-friendly
from the enough-to-make-you-sick dept.

One-shot cures for diseases are not great for business—more specifically, they’re bad for longterm profits—Goldman Sachs analysts noted in an April 10 report for biotech clients, first reported by CNBC.

The investment banks’ report, titled “The Genome Revolution,” asks clients the touchy question: “Is curing patients a sustainable business model?” The answer may be “no,” according to follow-up information provided.

[...] The potential to deliver “one shot cures” is one of the most attractive aspects of gene therapy, genetically engineered cell therapy, and gene editing. However, such treatments offer a very different outlook with regard to recurring revenue versus chronic therapies... While this proposition carries tremendous value for patients and society, it could represent a challenge for genome medicine developers looking for sustained cash flow.

[...] Ars reached out to Goldman Sachs, which confirmed the content of the report but declined to comment.


Original Submission

 
This discussion has been archived. No new comments can be posted.
Display Options Threshold/Breakthrough Mark All as Read Mark All as Unread
The Fine Print: The following comments are owned by whoever posted them. We are not responsible for them in any way.
  • (Score: 2) by qzm on Monday April 16 2018, @01:39AM

    by qzm (3260) on Monday April 16 2018, @01:39AM (#667451)

    much MUCH more than that.

    These companies enjoy a special, place protected by both questionable intellectual property protections (they are allowed to 'own' often natural
    compounds because they found a use for them - like giving the first person who found that oil could burn a patent over burning oil), and by having
    regulatory capture, whereby only certain companies are even allowed to supply these types of products because 'medical'.

    However, basically NOTHING is required in return for this special position.
    That is inequitable to society, and society should demand a more equitable situation, or remove those protections.

    And that, ladies and gentlemen, is entirely compatible with not only current market philosophy, but is actually demanded by accepted natural law.
    The thing standing in the way is of course corruption allowed by these companies backdooring huge money in to political decision making processes.

    Their cries of 'We need the money for research, we are only doing this for the good of humankind' is such an obvious lie these days that it is beyond laughable.

    Starting Score:    1  point
    Karma-Bonus Modifier   +1  

    Total Score:   2